Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antithrombin for Prevention of ARDS in COVID-19
NCT04745442Phase 2Completed
- Sponsor
- Maimónides Institute of Biomedical Research of Córdoba
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of antithrombin III in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Maimónides Institute of Biomedical Research of Córdoba. Primary endpoint: Combined variable: mortality or worsening rate with need for non-invasive or invasive mechanical ventilation at Day 31. Started Apr 2020; status: completed.
02
Drugs
antithrombin III
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04745442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745442.